How do new insights from the XARENO study impact treatment options for patients with AF and advanced CKD? In this episode, Dr Manesh Patel and Dr Peter Rossing expand upon the XARENO 2-year outcomes data presented at the ACC 2023 congress. The experts provide cardiology and endocrinology perspectives into how these results add to the wealth of randomized clinical trial and real-world data to determine the treatment options for patients with AF and advanced CKD. The views and opinions expressed throughout this podcast are those of the speakers based on their expertise and do not necessarily ref ..read more

This podcast is a follow-up to Bayer’s symposium at ESC 2022, ‘The beginning of the end for NOACs? The extra mile’. In this episode, Dr Manesh Patel and Professor Rupert Bauersachs expand on the discussions from the symposium, providing further insight into the management of frail patients with AF and VTE. The experts also provide their perspectives on the treatment of paediatric patients with VTE and patients with cancer-associated thrombosis, evaluating the available evidence to guide decision-making for these particularly vulnerable patients. The views and opinions expressed throughout this ..read more

In this episode, Professor Jan Beyer-Westendorf and Professor Rupert Bauersachs discuss the latest real-world evidence for the extended treatment of patients with venous thromboembolism (VTE). They focus on data published from the all-comer Dresden NOAC Registry, which provides important insights on the adherence patterns of patients with VTE on anticoagulation treatment beyond 12 months. Our experts also discuss the FIRST and SWIVTER registries, and how their findings highlight the importance of patient preference in maintaining patient persistence with extended treatment in order for patient ..read more

In this podcast, Dr Manesh Patel, Professor Reinhold Kreutz and Dr Andrew Steele discuss the results of the XARENO study and its implications for patients with AF and chronic kidney disease. This group of experts share their insights on how cardiologists and nephrologists can work most effectively together in multi-disciplinary teams to provide optimal care for these patients. The views and opinions expressed throughout this podcast are those of the speakers based on their expertise and do not necessarily reflect those of Bayer AG. Further details: • The paper on the rationale and design of th ..read more

In this episode, Professor Jan Beyer-Westendorf and Dr Cecilia Becattini discuss the treatment of vulnerable patients with venous thromboembolism. In particular, they focus on the treatment of patients who have received the devastating diagnosis of pulmonary embolism. Other specific patient groups are also discussed, including patients who are considered vulnerable and therefore carry a significant additional burden, even beyond the heavy load afforded by a VTE diagnosis. These include frail patients, children and those who are also navigating a cancer diagnosis and treatment. Practical guidan ..read more

This podcast is a follow-up to Bayer’s symposium at EHRA 2022 ‘What if? Protecting your patients with AF from stroke, no matter their journey.’ In this discussion, Professor John Camm and Professor Keith Fox provide further insight as to why patients with AF undergoing PCI need such close attention when choosing an antithrombotic regimen. They also explore additional considerations for the management of patients with AF undergoing elective PCI. Finally, the experts provide their perspectives on how patients with AF undergoing catheter ablation can be best protected from cardioembolic stroke. T ..read more

In this episode, Dr Sonia Anand and Professor Rupert Bauersachs discuss practical perspectives on how vascular surgeons can improve outcomes in patients with symptomatic PAD undergoing peripheral revascularization. Further details: • The results of the COMPASS trial can be found here: https://www.nejm.org/doi/full/10.1056/nejmoa1709118 • A subgroup analysis of patients with PAD in the COMPASS trial can be accessed here: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32409-1/fulltext • A subanalysis of the COMPASS trial investigating the net clinical benefit of dual pathway ..read more

In this episode, Professor Cihan Ay and Dr Jeffrey Weitz and provide an overview of the evidence base for the use of rivaroxaban in CAT, including randomized controlled clinical trials, real-world studies and data regarding patient satisfaction and quality of life. Further details: • The paper on the CLOT trial investigating the efficacy of dalteparin versus oral anticoagulation in preventing recurrent thrombosis in patients with cancer is available here: https://www.nejm.org/doi/full/10.1056/nejmoa025313 • Papers on the five randomized controlled trials comparing NOACs with dalteparin for the ..read more

This podcast is a follow up to Bayer’s symposium at ESC 2021 ‘Evolving Cardiovascular Risk: Your Patient’s Past, Present and Future’. Following on from the discussions at that meeting, Professor Craig Coleman and Professor Roxana Mehran provide further expert perspectives on the importance of considering your patient’s kidney function when they have atrial fibrillation, and discuss how to protect patients from the devastating effects of stroke. Professor Manesh Patel and Dr Rónán Collins then focus on stroke prevention in older patients with atrial fibrillation and highlight the fascinating st ..read more

In this episode, Dr Sonia Anand and Professor Rupert Bauersachs discuss practical perspectives on how vascular surgeons can improve outcomes in patients with symptomatic PAD undergoing peripheral revascularization. Further details: • The results of the COMPASS trial can be found here: https://www.nejm.org/doi/full/10.1056/nejmoa1709118 • A subgroup analysis of patients with PAD in the COMPASS trial can be accessed here: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32409-1/fulltext • A subanalysis of the COMPASS trial investigating the net clinical benefit of dual pathway ..read more